Dr. Tempero on New Therapies for Pancreatic Cancer

Margaret A. Tempero, MD
Published Online: Monday, January 13, 2014
Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, gives an overview of new therapies for pancreatic cancer.

Pathways that are downstream of activated RAS, such as the MAPK and PI3K pathways, are potential targets for the treatment of pancreatic cancer.

Tempero says that stromal depleting agents are also in development. There is also an interest in optimizing vaccine strategies and changing the immune cell population in the microenvironment from a pro-tumor environment to an anti-tumor environment.

Online CME Activities
Free CME from PER
PARP Inhibitors: Current and Future Options for Breast and Ovarian Cancer
Rapid Summaries and Commentaries: Update from Chicago - Advances in the Treatment of Lung Cancer
Medical Crossfire®: The JAK-STAT Pathway as a Mediator of Onco-Inflammation
2nd Annual Miami Lung Cancer Conference™ Medical Crossfire® Case Discussion
More Reading
$auto_registration$